Transfection Reagent and Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method (Electroporation, Liposomes, Particle Bombardment, Microinjection, Adenoviral Vectors, Calcium Phosphate, DEAE-dextran, Magnetic Beads, Activated Dendrimers, Laserfection), By Application (Gene Expression Studies, Protein Production, Transgenic Models, Therapeutic Delivery, Cancer Research, Biomedical Research), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.31 Billion
CAGR (2026-2031)	9.91%
Fastest Growing Segment	Electroporation
Largest Market	North America
Market Size (2031)	USD 2.31 Billion

Market Overview

The Global Transfection Reagent and Equipment Market will grow from USD 1.31 Billion in 2025 to USD 2.31 Billion by 2031 at a 9.91% CAGR. Transfection reagents and equipment comprise the chemical formulations and physical instruments utilized to introduce exogenous nucleic acids into cells for gene analysis and protein expression. The market is primarily supported by the rapid expansion of the biopharmaceutical research sector and the increasing volume of advanced therapeutic candidates entering clinical trials. This surge in research activity necessitates reliable delivery systems for vector manufacturing and directly fuels industry demand. According to the American Society of Gene & Cell Therapy, in 2024, there were more than 4,000 gene, cell, and RNA therapies in development globally. This extensive pipeline highlights the critical need for efficient transfection tools to support the growing field of genetic medicine.

Despite this positive growth trajectory the market faces a significant challenge regarding the cellular toxicity associated with many transfection methods. Chemical reagents and physical techniques frequently induce cellular stress or death which compromises experimental validity and reduces production yields in manufacturing. Researchers often struggle to maintain a balance between high delivery efficiency and cell viability particularly when scaling up for industrial applications. Consequently the technical difficulty in preserving cellular health during the transfection process remains a critical obstacle that complicates the broader commercial expansion of these technologies.

Key Market Drivers

The rapid expansion of cell and gene therapy research serves as the primary catalyst for the global transfection reagent and equipment market. As biopharmaceutical developers transition from early-stage discovery to commercial-scale manufacturing, the requirement for high-efficiency transfection technologies to produce viral vectors and engineer cell-based therapies has intensified. This trend is directly validated by recent regulatory successes; according to the International Society for Cell & Gene Therapy, in January 2025, it was reported that seven distinct cell and gene therapy products received FDA approval in 2024. Such approvals necessitate robust supply chains for transfection-grade plasmids and lipid nanoparticles, driving recurring revenue for reagent suppliers. To support this escalating commercial demand, major pharmaceutical entities are heavily expanding their production capabilities. For instance, according to Clinical Trials Arena, in October 2024, GSK invested $800 million in new drug substance and product manufacturing facilities in the United States, underscoring the massive capital flow into infrastructure that relies on advanced transfection workflows.

Growth in government initiatives and funding for biomedical sciences further accelerates the adoption of transfection technologies by lowering financial barriers for academic and industrial laboratories. Public sector grants and manufacturing funds are critical for modernizing research infrastructure, allowing scientists to procure advanced electroporation systems and novel chemical reagents. A prime example of this fiscal support occurred when, according to the UK Government, in November 2024, a £520 million commitment was announced for the Life Sciences Innovative Manufacturing Fund to bolster domestic production resilience. This influx of capital not only subsidizes the high costs associated with next-generation transfection equipment but also de-risks the development of novel non-viral delivery vectors. Consequently, state-sponsored financial stimuli are effectively widening the customer base, enabling smaller biotech firms and university hubs to integrate sophisticated transfection methods into their standard operational workflows.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the Global Transfection Reagent and Equipment Market is the inherent cellular toxicity associated with transfection methods, which directly undermines manufacturing efficiency and experimental success. When chemical reagents or physical instruments breach cell membranes to introduce nucleic acids, they frequently trigger cytotoxicity, leading to significant cell death or altered cellular behavior. This reduction in cell viability is particularly detrimental during the scale-up phase of biopharmaceutical production, where maintaining high yields of healthy cells is essential for the commercial viability of gene therapies and viral vectors. Consequently, the financial risks associated with batch failures force manufacturers to limit production runs, slowing the broader adoption of these technologies.

According to the American Society of Clinical Oncology (ASCO), in 2024, manufacturing data indicated that out-of-specification (OOS) rates for certain commercial cell therapy products reached as high as 28%, with low cell viability identified as a primary contributing factor. Such high failure rates underscore the critical bottleneck caused by cytotoxic stress during production. This unreliability necessitates repeated manufacturing cycles and extensive quality control measures, inflating the cost of goods sold and creating a substantial obstacle to market expansion.

Key Market Trends

The transition to GMP-grade reagents for clinical manufacturing is reshaping the market as gene therapy developers increasingly demand raw materials that meet stringent regulatory standards. As therapeutic candidates progress from early research to commercialization, suppliers are aggressively acquiring specialized capabilities to provide transfection formulations compliant with Good Manufacturing Practices. This industry consolidation is evident in high-value strategic acquisitions targeting premium reagent producers to secure supply chain reliability. According to Merck KGaA, in May 2024, the company entered into a definitive agreement to acquire Mirus Bio for approximately $600 million to bolster its integrated viral vector manufacturing offer. This substantial investment underscores the critical pivot toward securing high-performance and regulatory-compliant transfection platforms essential for the scalable production of modern genetic medicines.

A simultaneous shift toward non-viral delivery systems is accelerating due to the need to overcome the safety and manufacturing limitations inherent in viral vectors. Lipid nanoparticles and other chemical transfection methods are increasingly preferred for delivering mRNA and gene-editing machinery directly into patients. This technical evolution is attracting significant venture capital into companies developing next-generation in vivo delivery technologies that bypass complex ex vivo manipulation. According to BioSpace, in March 2024, Capstan Therapeutics raised $175 million in an oversubscribed Series B financing to advance its pipeline of in vivo CAR-T therapies which rely on targeted non-viral transfection. Such capital infusions highlight the growing market confidence in non-viral mechanisms as the future standard for administering complex biologic drugs.

Segmental Insights

The Electroporation segment is projected to be the fastest-growing category within the Global Transfection Reagent and Equipment Market, primarily driven by the rapid expansion of the cell and gene therapy sectors. This physical transfection method is increasingly preferred for its superior efficiency in delivering nucleic acids into difficult-to-process primary and stem cells, effectively addressing the limitations of chemical alternatives. Furthermore, the industry-wide shift toward non-viral delivery systems to mitigate immunogenicity risks aligns with safety standards from regulatory authorities like the U.S. FDA. Consequently, biopharmaceutical companies are actively integrating this technology to achieve scalable, clinical-grade manufacturing for emerging therapeutic applications.

Regional Insights

North America maintains a leading position in the global transfection reagent and equipment market, driven by substantial investments in biomedical research and a high concentration of major biotechnology firms. The region benefits from significant funding initiatives for life sciences supported by institutions like the U.S. National Institutes of Health, which accelerates the development of novel therapeutics. Additionally, the increasing focus on cell and gene therapies necessitates reliable transfection methods. This growth is further sustained by a well-established healthcare infrastructure and supportive frameworks provided by regulatory bodies such as the U.S. Food and Drug Administration.

Recent Developments

• In July 2024, STEMCELL Technologies commercially launched the CellPore Transfection System, a benchtop instrument designed to advance cell engineering research. This system employs a proprietary mechanoporation technology that delivers cargo into cells by rapidly deforming them through microfluidic channels to create transient pores in the cell membrane. Unlike traditional electroporation techniques, this method enables the gentle and efficient delivery of a wide variety of molecules, including nucleic acids and proteins, into mammalian cells while maintaining high cell viability. This product launch offers a scalable solution for intracellular delivery, supporting the development of novel cell therapies.
• In June 2024, Amerigo Scientific announced the commercial launch of a comprehensive new line of transfection reagents tailored for the efficient delivery of DNA, RNA, and proteins into cells. The newly introduced products include specialized kits, such as the LipoMag kit, which are formulated to ensure high transfection efficiency with minimal cytotoxicity across a diverse range of cell types. These reagents are designed to facilitate critical applications in molecular biology, including gene expression studies, therapeutic protein production, and gene therapy research, providing researchers with reliable tools to introduce genetic material into difficult-to-transfect cells.
• In May 2024, MaxCyte, Inc. entered into a strategic platform license agreement with Legend Biotech to support the development of next-generation cell therapies. Under the terms of this collaboration, the partner company obtained non-exclusive worldwide rights to utilize MaxCyte’s Flow Electroporation technology and ExPERT platform for the research, clinical development, and commercialization of its cell-based medicines. This agreement allows the partner to leverage advanced non-viral cell engineering capabilities to optimize manufacturing processes for various cell types, including T cells and natural killer cells, thereby enhancing the scalability and efficiency of their therapeutic pipeline.
• In January 2024, Asimov, Inc. announced the launch of its LV Edge Packaging System, a novel solution designed to optimize the manufacturing of lentiviral vectors. This new system enables viral vector production through a single-plasmid transfection process, significantly reducing the complexity and cost associated with the traditional multi-plasmid transfection workflows. The platform integrates a clonal packaging cell line with stable viral gene integration and computer-aided DNA design software to maximize viral titers. This product launch addresses critical supply chain and efficiency challenges in the cell and gene therapy market by streamlining the transfection and production steps for therapeutic developers.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Promega Corporation
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Inc.
• Merck KGaA
• OriGene Technologies Inc.
• MaxCyte, Inc.
• POLYPLUS TRANSFECTION S.A.
• Horizon Discovery Ltd.
• PromoCell GmbH

By Method	By Application	By Region
Electroporation Liposomes Particle Bombardment Microinjection Adenoviral Vectors Calcium Phosphate DEAE-dextran Magnetic Beads Activated Dendrimers Laserfection	Gene Expression Studies Protein Production Transgenic Models Therapeutic Delivery Cancer Research Biomedical Research	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Transfection Reagent and Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Transfection Reagent and Equipment Market, By Method:

• Electroporation
• Liposomes
• Particle Bombardment
• Microinjection
• Adenoviral Vectors
• Calcium Phosphate
• DEAE-dextran
• Magnetic Beads
• Activated Dendrimers
• Laserfection

• Transfection Reagent and Equipment Market, By Application:

• Gene Expression Studies
• Protein Production
• Transgenic Models
• Therapeutic Delivery
• Cancer Research
• Biomedical Research

• Transfection Reagent and Equipment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE